whitepaper
Transform your drug discovery pipeline with 3D cellular models
7 July 2025 | By Molecular Devices
Expert insights reveal how 3D cellular models are revolutionising preclinical testing and clinical translation.
List view / Grid view
Clinical Trials
article
Future-proofing drug development with GenAI
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
article
The AI model that is changing clinical trial design
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
news
‘Delete-to-recruit’: new gene-editing method targets sickle cell
Researchers have developed a novel gene therapy approach that reactivates dormant genes by repositioning them closer to genetic switches called enhancers - showing promise for treating blood disorders like sickle cell disease.
podcasts
Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
article
Pain relief without the risk: why SRP-001 could change everything
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
news
New therapy for incurable brain disease heads to clinical trials
SynaptixBio has selected its lead drug candidate, SB H-19642, for clinical trials to treat H-ABC - a rare, fatal neurodegenerative disease with no current cure.
article
From siloed data to breakthroughs: multimodal AI in drug discovery
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
news
Statins repurposed for sepsis show life-saving potential
A new study suggests statins, cheap and widely used cholesterol drugs, could be repurposed to reduce the risk of death from sepsis. Researchers reported a 39 percent drop in 28-day mortality, highlighting their potential role in critical care.
news
New UCD centre targets the biggest bottleneck in rare research
The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.
article
New fixed-duration therapy could reshape CLL care
Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment…
article
Transforming cancer care through clinical excellence
Melika Davis at BeOne reflects on the inspiration and drive that has helped her forge a successful career in clinical operations.
news
Targeting the clock: new drug disrupts glioblastoma stem cells
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
article
AACR 2025: translating research into real-world impact
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
article
Building the requisite clinical development infrastructure for medical innovation to thrive
Outdated clinical development systems are slowing breakthroughs like gene therapies and precision medicine. This article explores how a flexible, on-demand approach can accelerate drug development and bring innovations to patients faster.
